| Identification | Back Directory | [Name]
B-HT 920 DIHYDROCHLORIDE | [CAS]
36085-73-1 | [Synonyms]
b-ht920
4H-Thiazolo[4
B-HT 920 2HCl
5-d]azepin-2-aMine
hydrochloride (1:2)
Hydrochloric talipexole
B-HT 920 (hydrochloride)
B-HT 920 DIHYDROCHLORIDE
talipexole hydrochloride
talipexoledihydrochloride
TALIPEXOLE DIDHYDROCHLORIDE
8-tetrahydro-6-(2-propen-1-yl)-
B-HT920dihydrochlorideTalipexole
Talipexole dihydrochloride(B-HT 920)
B-HT 920 DIHYDROCHLORIDE A2 ADRENOCEPTOR AGONI
2-amino-6-allyl-4,5,7,8-tetrahydro-6h-thiazolo(5,4-d)azepin-dihydrochlorid
5-d)azepin-2-amine,5,6,7,8-tetrahydro-6-(2-propenyl)-4h-thiazolo(dihydroch
6-Allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine-2-amine dihydrochloride
5,6,7,8-tetrahydro-6-(2-propenyl)-4h-thiazolo(4,5-d)azepin-2-aminedihydrochl
6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO[4,5-D]AZEPINE DIHYDROCHLORIDE
5,6,7,8-TETRAHYDRO-6-(2-PROPENYL)-4H-THIAZOLO[4,5-D]AZEPIN-2-AMINE DIHYDROCHLORIDE
5,6,7,8-TETRAHYDRO-6-(2-PROPENYL)-4H-THIAZOLO[4,5-D]AZEPINE-2-AMINE DIHYDROCHLORIDE
2-Amino-6-allyl-4,5,7,8-tetrahydro-6H-thiazolo(5,4-D)azepin-dihydrochlorid [german]
4H-Thiazolo(4,5-D)azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-, dihydrochloride
5,6,7,8-Tetrahydro-6-(2-propen-1-yl)-4H-thiazolo[4,5-d] azepin-2-amine dihydrochloride
Talipexole, 5,6,7,8-Tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepine-2-amine dihydrochloride
5,6,7,8-Tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amineDihydrochloride,6-Allyl-2-amino-5,6,7,8-tetrahydro-4
5,6,7,8-Tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine Dihydrochloride, 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine Dihydrochloride | [Molecular Formula]
C10H17Cl2N3S | [MDL Number]
MFCD00274573 | [MOL File]
36085-73-1.mol | [Molecular Weight]
282.23 |
| Chemical Properties | Back Directory | [Appearance]
Light Yellow Solid | [Melting point ]
245°C dec. | [storage temp. ]
Desiccate at RT | [solubility ]
H2O: >20 mg/mL
| [form ]
solid
| [color ]
off-white |
| Hazard Information | Back Directory | [Chemical Properties]
Light Yellow Solid | [Uses]
An alpha 2-Adrenoceptor and dopamine D2-receptor agonist. Used as an antiparkinson reagent | [Biological Activity]
Dopamine D 2 receptor agonist, α 2 -adrenoceptor agonist and 5-HT 3 receptor antagonist. Displays antiParkinsonian activity. | [Description]
B-HT 920 is a potent agonist of dopamine 2 (D2) receptors (Ki = 5.8 nM) that shows selectivity for D2 over D3 and D4 receptors.1,2,3 It has neuroprotective and regenerative effects in animal models of Parkinson’s disease.4 B-HT 920 is also an agonist of α2-adrenergic receptors and an antagonist of serotonin-3 (5-HT3; Ki = 0.35 μM) receptors.5,6 | [Definition]
ChEBI: Talipexole dihydrochloride is an azepine. | [References]
[1] FRANCIS K. MAINA Tiffany A M. Functional Fast Scan Cyclic Voltammetry Assay to Characterize Dopamine D2 and D3 Autoreceptors in the Mouse Striatum[J]. ACS Chemical Neuroscience, 2010, 1 6: 450-462. DOI: 10.1021/cn100003u
[2] RICHARD E. MEWSHAW. New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D2 Agonist Pharmacophore. Structure?Activity Relationships of a Series of 2-(Aminomethyl)chromans[J]. Journal of Medicinal Chemistry, 1997, 40 26: 4235-4256. DOI: 10.1021/jm9703653
[3] G S ROBERTSON. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.[J]. Journal of Pharmacology and Experimental Therapeutics, 1993, 264 3: 1344-1351.
[4] KITAMURA Y. [Dopaminergic neuroprotection and reconstruction of neural network tiara].[J]. Yakugaku zasshi?: Journal of the Pharmaceutical Society of Japan, 2010, 130 10: 1263-1272. DOI: 10.1248/yakushi.130.1263
[5] HIROAKI NISHIO . 5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole[J]. General Pharmacology-the Vascular System, 1996, 27 5: Pages 779-785. DOI: 10.1016/0306-3623(95)02125-6
[6] DANIEL RICCI Carlos A T. Adrenoceptor Involvement in the Cardiovascular Responses to B-HT 920 in Sinoaortic Denervated Rats[J]. General Pharmacology-the Vascular System, 1999, 32 1: Pages 29-34. DOI: 10.1016/s0306-3623(98)00018-4 |
|
|